Prof. dr. Marcel Karperien completed his study in biology at Utrecht University, the Netherlands in 1991. After graduation he started his PhD training at the Hubrecht laboratory in Utrecht where he started working on bone development during embryogenesis.
He performed part of his PhD research at the Endocrine Unit of Harvard Medical School. He continued his scientific career at the Leiden University Medical Center where he successfully started a research group working on growth plate biology, growth disorders and metabolic bone diseases. In 2007 he moved to the University of Twente where he started the Developmental BioEngineering group. In 2013 he became full professor. His research group, which currently contains 40 people, is focused on the development of technology inspired solutions for cartilage repair and joint diseases (https://people.utwente.nl/marcel.karperien?tab=about-me). His scientific work has, amongst others, led to the ground breaking hydrogel technology for cell-free and in situ cartilage repair which forms the technological basis of Hy2Care. In 2014 Marcel Karperien founded the company Hy2Care to bring this technology into patients. Currently he holds a position as CSO and is a member of Hy2Care’s supervisory board. Marcel Karperien has co-authored more than 230 scientific papers, is inventor on 7 granted patent applications that have been licensed to spin off companies of his group of which Hy2Care is one of them. For his scientific work, Marcel Karperien has received awards from the American Society for Bone and Mineral Research, the European Calcified Tissue Society, the Dutch Society for Endocrinology. His research group has been awarded the status of Research Center of Excellence in Osteoarthritis Research by ReumaNederland.
“Hy2Care provides me the means to complete the developmental cycle for our hydrogel technology, which my team developed within the University, and to actually bring this technology from the lab bench into human and animal patients”